Leadership Overview
Daiichi Sankyo has 8 executives leading key functions including financial strategy, oncology medical affairs, executive operations, global systems, financial planning, clinical development, and regional leadership.
Driven by a commitment to medical innovation, Daiichi Sankyo delivers advanced pharmaceutical solutions and drug discovery methods to patients across more than 30 countries worldwide.
Driven by a commitment to medical innovation, Daiichi Sankyo delivers advanced pharmaceutical solutions and drug discovery methods to patients across more than 30 countries worldwide.
Leadership Roles at Daiichi Sankyo
Kazuki Mori - Chief of Staff To Chief Executive Officer
Kazuki Mori, the Chief of Staff To Chief Executive Officer at Daiichi Sankyo, manages the strategic priorities and daily operations of the executive office. Facilitating communication between the Chief Executive Officer and senior leadership, the Chief of Staff To Chief Executive Officer ensures the seamless execution of corporate initiatives across all global departments. This leadership role involves synthesizing complex data to support high-level decision-making regarding pharmaceutical market expansion and drug discovery investments. By maintaining organizational focus, Kazuki Mori directly impacts the efficiency of the executive team. Furthermore, Mori coordinates board-level reporting and monitors the progress of long-term strategic goals. Through proactive management of executive workflows, the Chief of Staff To Chief Executive Officer enables the leadership team to concentrate on the core mission of developing and providing innovative medicines to patients in over 30 countries.
Bruno Luiz de Vicente Cadastro - Chief Financial Officer
Bruno Luiz de Vicente Cadastro, the Chief Financial Officer at Daiichi Sankyo, directs all global fiscal operations and capital allocation strategies. Managing the financial health of the organization, the Chief Financial Officer ensures rigorous oversight of budgetary compliance and investment in drug discovery pipelines. This leadership role involves coordinating with international stakeholders to maintain fiscal stability across diverse pharmaceutical markets. By optimizing resource distribution, Bruno Luiz de Vicente Cadastro directly impacts the company's ability to fund advanced research and development initiatives. Furthermore, Cadastro monitors economic trends to mitigate risks associated with global drug distribution. Through precise financial modeling and strategic planning, the Chief Financial Officer supports the long-term growth objectives of the firm, ensuring that capital remains aligned with the core mission of providing innovative medicines to patients in over 30 countries.
Chloe Stern - Manager, Chief Financial Officer Planning Department
Chloe Stern, the Manager, Chief Financial Officer Planning Department at Daiichi Sankyo, executes detailed financial forecasting and long-range planning for the pharmaceutical business. Analyzing market trends and operational costs, the Manager, Chief Financial Officer Planning Department provides the data-driven insights necessary for effective capital budgeting. This leadership role involves collaborating with various departments to ensure that financial plans reflect the specific requirements of drug development and commercialization. By refining planning methodologies, Chloe Stern directly impacts the accuracy of the company's financial projections. Furthermore, Stern monitors performance metrics to identify opportunities for cost optimization and resource reallocation. Through the development of comprehensive financial strategies, the Manager, Chief Financial Officer Planning Department supports the overall fiscal health of the organization, ensuring that resources are effectively directed toward the company's goal of providing innovative medicines to patients.
Suthas Thongprasert - President
Suthas Thongprasert, the President at Daiichi Sankyo, drives the strategic direction and commercial success of regional operations. Overseeing market expansion and local pharmaceutical distribution, the President ensures that the company's innovative medicines reach patients effectively within the assigned territory. This leadership role involves building strong relationships with healthcare stakeholders and navigating complex regulatory environments to maintain market presence. By fostering a culture of operational excellence, Suthas Thongprasert directly impacts the growth and profitability of the regional business unit. Furthermore, Thongprasert coordinates with global headquarters to align regional activities with the overarching corporate mission of drug discovery and delivery. Through decisive leadership and market-focused strategies, the President secures the company's position as a leader in the pharmaceutical industry, ensuring that patients have access to advanced treatments.
Naoki Hatakeyama - President
Naoki Hatakeyama, the President at Daiichi Sankyo, manages the strategic integration of pharmaceutical manufacturing and supply chain logistics. Overseeing the production of innovative and generic medicines, the President ensures that quality standards and delivery timelines are consistently met across the supply network. This leadership role involves optimizing manufacturing processes to support the company's global drug discovery and delivery methods. By enhancing operational efficiency, Naoki Hatakeyama directly impacts the availability of essential medications for patients in over 30 countries. Furthermore, Hatakeyama leads initiatives to modernize production facilities and adopt advanced manufacturing technologies. Through the implementation of robust operational strategies, the President supports the company's mission to provide high-quality pharmaceutical solutions, ensuring that the organization remains responsive to the evolving needs of the global healthcare market.
Caitlin Barnabo - Global Oncology Medical Affairs Chief of Staff
Caitlin Barnabo, the Global Oncology Medical Affairs Chief of Staff at Daiichi Sankyo, coordinates strategic initiatives within the oncology division to accelerate the delivery of breakthrough cancer treatments. Overseeing cross-functional collaboration, the Global Oncology Medical Affairs Chief of Staff ensures that clinical data effectively reaches healthcare providers and patient communities. This leadership role involves managing complex communication workflows and aligning medical affairs objectives with global clinical development goals. By streamlining internal processes, Caitlin Barnabo directly impacts the speed and efficacy of oncology product launches. Furthermore, Barnabo facilitates engagement with key opinion leaders to advance the understanding of novel drug delivery methods. Through meticulous project management and strategic oversight, the Global Oncology Medical Affairs Chief of Staff maintains the high standards of medical excellence required to support the company's expanding portfolio of innovative oncology medicines.
Kosuke Itagaki - Chief of Staff & Global System Owner
Kosuke Itagaki, the Chief of Staff & Global System Owner at Daiichi Sankyo, architects the digital infrastructure and operational systems that support global pharmaceutical workflows. Overseeing the integration of advanced technology, the Chief of Staff & Global System Owner ensures that data management platforms remain scalable and secure across all international regions. This leadership role involves aligning system capabilities with the specific needs of drug discovery and clinical development teams. By optimizing technical processes, Kosuke Itagaki directly impacts the operational efficiency of the entire organization. Furthermore, Itagaki manages the lifecycle of critical enterprise systems to ensure compliance with global regulatory standards. Through the implementation of robust digital solutions, the Chief of Staff & Global System Owner facilitates the seamless flow of information necessary to support the company's mission of delivering innovative medicines to patients worldwide.
John Harkins - Senior Director, Chief of Staff, Global Oncology Clinical Development
John Harkins, the Senior Director, Chief of Staff, Global Oncology Clinical Development at Daiichi Sankyo, directs the operational strategy for clinical trials and oncology research programs. Overseeing the coordination of global development teams, the Senior Director, Chief of Staff, Global Oncology Clinical Development ensures that clinical milestones are met with precision and regulatory compliance. This leadership role involves managing the complex logistics of multi-country clinical studies to advance the company's oncology pipeline. By streamlining development workflows, John Harkins directly impacts the timeline for bringing new cancer treatments to market. Furthermore, Harkins facilitates communication between clinical researchers and executive leadership to ensure alignment with corporate goals. Through rigorous oversight of clinical operations, the Senior Director, Chief of Staff, Global Oncology Clinical Development supports the company's commitment to providing innovative medicines to patients in over 30 countries.
Explore Leadership Teams in Manufacturing
Bristol-Myers Squibb operates as a global biopharmaceutical organization dedicated to discovering, developing, and manufacturing prescription medications that address serious patient needs across multiple therapeutic domains. The company's scientific expertise spans oncology, cardiovascular disease, immunoscience, and virology, with particular depth in treating complex conditions including HIV and cancer. Through sustained investment in research and development, the organization has built a comprehensive medication portfolio that combines innovative cancer immunotherapies, anticoagulant therapies, and treatments for chronic viral infections. The company's operational footprint extends across major markets worldwide, enabling efficient distribution and patient access to its therapeutic solutions. Bristol-Myers Squibb pursues a collaborative approach to medical innovation, actively engaging in research partnerships and strategic alliances that accelerate the development of new treatment options. This commitment to external collaboration complements the organization's internal capabilities, creating a dynamic environment where scientific breakthroughs can translate into meaningful therapeutic advances. Bristol-Myers Squibb's medication portfolio reflects decades of pharmaceutical expertise and a strategic focus on disease areas where unmet medical needs remain significant.
Company Leadership IC
HA
NM
BS
Founded in 1947 and headquartered in Mumbai, Indoco Remedies Limited is a fully integrated, research-oriented pharma company. Indoco specializes in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).
Company Leadership
PA
AR
Telix Pharmaceuticals is a global, commercial-stage biopharmaceutical company headquartered in North Melbourne, Australia, publicly listed on the Australian Securities Exchange and Nasdaq under the ticker TLX. The company specializes in the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, commonly referred to as theranostics, which use molecularly targeted radiation to both image and treat cancer. Telix's pipeline is focused on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. Its lead commercial product, Illuccix, is an approved PSMA-PET/CT imaging agent for prostate cancer with regulatory clearance from the FDA, Australia's TGA, and Health Canada.
Company Leadership KR
CB
DS
Avara Pharmaceutical Services is a manufacturing organization. It offers aseptic liquid filling, sterile pharmaceutical, oral solid dose, packaging solutions and sterile injectables. The company was founded in 2015 and is located in Norman, Oklahoma.
Company Leadership CA
RM
RR
Frequently Asked Questions Regarding Daiichi Sankyo Top Executives and Leadership Team
